Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin.

PURPOSE To evaluate the accuracy and clinical utility of the Outpatient Bleeding Risk Index for estimating the probability of major bleeding in outpatients treated with warfarin. The index was previously derived in a retrospective cohort of 556 patients from a different hospital (derivation cohort). SUBJECTS AND METHODS We enrolled 264 outpatients starting warfarin (validation cohort) to validate the index prospectively. All patients were identified upon hospital discharge, and physician estimates of the probability of major bleeding were obtained before discharge in the validation cohort. RESULTS Major bleeding occurred in 87 of 820 outpatients (6.5%/yr). The index included four independent risk factors for major bleeding: age 65 years or greater; history of gastrointestinal bleeding; history of stroke; and one or more of four specific comorbid conditions. In the validation cohort, the index predicted major bleeding: the cumulative incidence at 48 months was 3% in 80 low-risk patients, 12% in 166 intermediate-risk patients, and 53% in 18 high-risk patients (c index, 0.78). The index performed better than physicians, who estimated the probability of major bleeding no better than expected by chance. Of the 18 episodes of major bleeding that occurred in high-risk patients, 17 were potentially preventable. CONCLUSIONS The Outpatient Bleeding Risk Index prospectively classified patients according to risk of major bleeding and performed better than physicians. Major bleeding may be preventable in many high-risk patients by avoidance of over-anticoagulation and nonsteroidal anti-inflammatory agents.

[1]  C. Bjerkelund Therapeutic level in long term anticoagulant therapy after myocardial infarction. Its relation to recurrent infarction and sudden death. , 1963, The American journal of cardiology.

[2]  J. Wasson,et al.  Physician variation in anticoagulating patients with atrial fibrillation. Dartmouth Primary Care COOP Project. , 1990, Archives of internal medicine.

[3]  R. W. Achor,et al.  Problems Associated with Long‐Term Anticoagulant Therapy: Observations in 139 Cases , 1962, Circulation.

[4]  K. Moser,et al.  Risk of complications during intravenous heparin therapy. , 1982, The Western journal of medicine.

[5]  J. Avorn,et al.  Aging and the Anticoagulant Response to Warfarin Therapy , 1992, Annals of Internal Medicine.

[6]  L Goldman,et al.  Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions. , 1989, The American journal of medicine.

[7]  J. Bell,et al.  Physician Variation in Anticoagulating Patients With Atrial Fibrillation , 1990 .

[8]  J. Gurwitz,et al.  Age-related risks of long-term oral anticoagulant therapy. , 1988, Archives of internal medicine.

[9]  Daniel B. Mark,et al.  TUTORIAL IN BIOSTATISTICS MULTIVARIABLE PROGNOSTIC MODELS: ISSUES IN DEVELOPING MODELS, EVALUATING ASSUMPTIONS AND ADEQUACY, AND MEASURING AND REDUCING ERRORS , 1996 .

[10]  K. Uberla,et al.  Secondary prevention of myocardial infarction: a comparison of acetylsalicylic acid, placebo and phenprocoumon. , 1980, Haemostasis.

[11]  M Gent,et al.  Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. , 1991, Journal of the American College of Cardiology.

[12]  Gordon H. Guyatt,et al.  Users' Guides to the Medical Literature: V. How to Use an Article About Prognosis , 1994 .

[13]  L Goldman,et al.  Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. , 1989, The American journal of medicine.

[14]  V. Fidler,et al.  IMPROVED PRIMARY RENAL ALLOGRAFT SURVIVAL ON CYCLOSPORIN LIMITED TO WOMEN WITH PREVIOUS PREGNANCIES , 1989, The Lancet.

[15]  Neurology Section An evaluation of anticoagulant therapy in the treatment of cerebrovascular disease , 1961, Neurology.

[16]  S M Nazarian,et al.  Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. , 1992, The New England journal of medicine.

[17]  Vittorio Pengo,et al.  Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT) , 1996, The Lancet.

[18]  D. Petitti,et al.  Duration of warfarin anticoagulant therapy and the probabilities of recurrent thromboembolism and hemorrhage. , 1986, The American journal of medicine.

[19]  P Smith,et al.  The effect of warfarin on mortality and reinfarction after myocardial infarction. , 1990, The New England journal of medicine.

[20]  E. Enger,et al.  Long-term anticoagulant therapy in patients with cerebral infarction. A crontrolled clinical study. , 1965, Acta medica Scandinavica. Supplementum.

[21]  H. White,et al.  Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation : stroke prevention in atrial fibrillation II study. Commentary , 1994 .

[22]  Lippincott Williams Wilkins,et al.  Stroke Prevention in Atrial Fibrillation Study: Final Results , 1991, Circulation.

[23]  C. Fisher Anticoagulant therapy in cerebral thrombosis and cerebral embolism , 1961, Neurology.

[24]  Bernard Rosner,et al.  The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. , 1990, The New England journal of medicine.

[25]  Frank Davidoff,et al.  Predicting Clinical States in Individual Patients , 1996, Annals of Internal Medicine.

[26]  Z. J. Lipowski Letter: Psychosomatic medicine. , 1974, Lancet.

[27]  F. Harrell,et al.  Evaluating the yield of medical tests. , 1982, JAMA.

[28]  F. Mcdowell,et al.  Anticoagulant Therapy: Five Years Experience with the Patient with an Estadlished Cerebrovasculor Accident , 1963 .

[29]  A. Krogsgaard Reserpine and gastric secretion in man. , 2009, Acta medica Scandinavica.

[30]  F. Silverstone,et al.  Physicians' attitudes toward oral anticoagulants and antiplatelet agents for stroke prevention in elderly patients with atrial fibrillation. , 1991, Archives of internal medicine.

[31]  L K Gottlieb,et al.  Anticoagulation in Atrial Fibrillation: Does Efficacy in Clinical Trials Translate Into Effectiveness in Practice? , 1994 .

[32]  Donald Martin,et al.  Risk Factors for Complications of Chronic Anticoagulation: A Multicenter Study , 1993, Annals of Internal Medicine.

[33]  J. Vandenbroucke,et al.  Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. , 1993, Archives of internal medicine.

[34]  B. Gersh,et al.  Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rochester, Minnesota. , 1995, Mayo Clinic proceedings.

[35]  P. Patton Risk factors for complications of chronic anticoagulation , 1994 .

[36]  L. Goldman,et al.  The bleeding severity index: validation and comparison to other methods for classifying bleeding complications of medical therapy. , 1989, Journal of clinical epidemiology.

[37]  T. Hutchinson,et al.  Factors relevant to preventing embolic stroke in patients with non-rheumatic atrial fibrillation. , 1991, Journal of clinical epidemiology.

[38]  C. Landefeld,et al.  A bleeding risk index for estimating the probability of major bleeding in hospitalized patients starting anticoagulant therapy. , 1990, The American journal of medicine.

[39]  O. Meuwissen,et al.  Double blind trial of long-term anticoagulant treatment after myocardial infarction. , 2009, Acta medica Scandinavica.

[40]  L. Rydén,et al.  Haemorrhagic and thromboembolic complications in patients with atrial fibrillation on anticoagulant prophylaxis , 1989, Journal of internal medicine.

[41]  P Tugwell,et al.  Users' guides to the medical literature. V. How to use an article about prognosis. Evidence-Based Medicine Working Group. , 1994, JAMA.

[42]  Secondary Prevention of Myocardial Infarction , 1999 .

[43]  J. Heaf,et al.  Bleeding complications to oral anticoagulant therapy: multivariate analysis of 1010 treatment years in 551 outpatients , 1991, Journal of internal medicine.

[44]  J. Vandenbroucke,et al.  Bleeding Complications in Oral Anticoagulant Therapy , 1993 .

[45]  S. Fihn,et al.  The Risk for and Severity of Bleeding Complications in Elderly Patients Treated with Warfarin , 1996, Annals of Internal Medicine.

[46]  G. Samsa,et al.  Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. , 1995, Archives of internal medicine.

[47]  E F Cook,et al.  Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. , 1987, The American journal of medicine.

[48]  A. Gallus,et al.  Trial of different intensities of anticoagulation in patients with prosthetic heart valves. , 1990, The New England journal of medicine.

[49]  Palle Petersen,et al.  PLACEBO-CONTROLLED, RANDOMISED TRIAL OF WARFARIN AND ASPIRIN FOR PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN CHRONIC ATRIAL FIBRILLATION The Copenhagen AFASAK Study , 1989, The Lancet.

[50]  J. Toole,et al.  Anticoagulant therapy in cerebral infarction , 1962, Neurology.

[51]  P. W. Willis,et al.  Hemorrhagic complications of anticoagulant therapy. , 1974, Archives of internal medicine.